A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Capecitabine (Primary) ; Temozolomide (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 12 Dec 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2023.
- 12 Dec 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 10 Jun 2017 Biomarkers information updated